MCID: IDP093
MIFTS: 28

Idiopathic Gastroparesis

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Idiopathic Gastroparesis

MalaCards integrated aliases for Idiopathic Gastroparesis:

Name: Idiopathic Gastroparesis 58

Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Orphanet 58 ORPHA558411

Summaries for Idiopathic Gastroparesis

MalaCards based summary : Idiopathic Gastroparesis is related to gastroparesis and body mass index quantitative trait locus 11. An important gene associated with Idiopathic Gastroparesis is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are cAMP signaling pathway and Angiogenesis (CST). The drugs Neurotransmitter Agents and Gastrointestinal Agents have been mentioned in the context of this disorder. Related phenotypes are digestive/alimentary and homeostasis/metabolism

Related Diseases for Idiopathic Gastroparesis

Diseases related to Idiopathic Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
# Related Disease Score Top Affiliating Genes
1 gastroparesis 29.5 MRC1 HMOX1 GIP GHSR GHRL
2 body mass index quantitative trait locus 11 28.9 HMOX1 GIP GHSR GHRL
3 constipation 10.1
4 alzheimer disease 9 10.0 GHSR GHRL
5 postgastrectomy syndrome 10.0 GIP GHRL
6 growth hormone secreting pituitary adenoma 10.0 GHSR GHRL
7 dumping syndrome 10.0 GIP GHRL
8 ileus 10.0 GHSR GHRL
9 migraine with or without aura 1 9.9
10 cyclic vomiting syndrome 9.9
11 body mass index quantitative trait locus 9 9.9
12 body mass index quantitative trait locus 8 9.9
13 body mass index quantitative trait locus 4 9.9
14 body mass index quantitative trait locus 10 9.9
15 body mass index quantitative trait locus 7 9.9
16 body mass index quantitative trait locus 12 9.9
17 body mass index quantitative trait locus 14 9.9
18 body mass index quantitative trait locus 18 9.9
19 body mass index quantitative trait locus 19 9.9
20 hyperinsulinism 9.9
21 adenocarcinoma 9.9
22 pancreatic adenocarcinoma 9.9
23 neuromuscular disease 9.9
24 median arcuate ligament syndrome 9.9
25 48,xyyy 9.9
26 hypoganglionosis 9.9
27 autonomic dysfunction 9.9
28 acromegaly 9.8 GHSR GHRL
29 functional gastric disease 9.8 GIP GHSR GHRL
30 anorexia nervosa 9.7 GHSR GHRL
31 ectodermal dysplasia 1, hypohidrotic, x-linked 9.6 MRC1 HMOX1
32 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 9.6 MRC1 HMOX1
33 diabetes mellitus 9.3 HMOX1 GIP GHSR GHRL

Graphical network of the top 20 diseases related to Idiopathic Gastroparesis:



Diseases related to Idiopathic Gastroparesis

Symptoms & Phenotypes for Idiopathic Gastroparesis

MGI Mouse Phenotypes related to Idiopathic Gastroparesis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.26 GHRL GHSR GIP PDGFRA
2 homeostasis/metabolism MP:0005376 9.1 GHRL GHSR GIP HMOX1 MRC1 PDGFRA

Drugs & Therapeutics for Idiopathic Gastroparesis

Drugs for Idiopathic Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Neurotransmitter Agents Phase 4
2 Gastrointestinal Agents Phase 4
3 Antacids Phase 4
4 Anti-Ulcer Agents Phase 4
5 Serotonin Receptor Agonists Phase 4
6
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
7
Nortriptyline Approved Phase 3 72-69-5 4543
8 Antidepressive Agents Phase 3
9 Antidepressive Agents, Tricyclic Phase 3
10 Adrenergic Agents Phase 3
11 neurokinin A Phase 3
12
Substance P Phase 3 33507-63-0 44359816
13
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
14
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
15
Maleic acid Experimental Phase 2 110-16-7 444266
16 Antiemetics Phase 2
17 Dopamine Agents Phase 2
18 Dopamine Antagonists Phase 2
19 Cola Phase 2
20
Pioglitazone Approved, Investigational Early Phase 1 111025-46-8 4829
21
Olanzapine Approved, Investigational 132539-06-1 4585 135398745
22 Hypoglycemic Agents Early Phase 1
23 Psychotropic Drugs
24 Antipsychotic Agents
25 Serotonin Uptake Inhibitors

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
2 Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG) Completed NCT00765895 Phase 3 Nortriptyline Hydrochloride;Placebo (for nortriptyline)
3 VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis Recruiting NCT04028492 Phase 3 Tradipitant;Placebo
4 A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis Completed NCT03268941 Phase 2 TAK-906 Maleate;Metaclopramide;TAK-906 Maleate Placebo
5 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis Completed NCT02267525 Phase 2 Velusetrag;Placebo
6 A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase 2 Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis Completed NCT01718938 Phase 2 velusetrag dose 1;velusetrag dose 2;velusetrag dose 3;placebo
7 A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis Completed NCT03281577 Phase 2 TAK-954;Placebo
8 Effects of Global Osteopathic Manual Treatments on Patients With Idiopathic Gastroparesis Unknown status NCT02232334
9 GpR 2: Continuation of the NIDDK Gastroparesis Registry for the Characterization and Clinical Course of Gastroparesis Patients Completed NCT01696747
10 Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients Completed NCT01916460
11 Study of the Antro-pyloro-duodenal Motor Dysfunction in Idiopathic Gastroparesis Completed NCT01519180
12 Endoscopic Full Thickness Biopsy of the Gastric Wall in Patients With Refractory Idiopathic Gastroparesis: Pilot Study to Detect Neuromuscular and Immune Pathologic Changes Completed NCT01650714
13 Pioglitazone for the Treatment of Idiopathic Gastroparesis (PIOGAS Study) Recruiting NCT04300127 Early Phase 1 Pioglitazone 30 mg
14 A Pilot Study on the Efficacy and Safety of Olanzapine in Improving Symptoms and Gastric Motility in Gastroparesis Terminated NCT01625923 Olanzapine
15 Idiopathic Gastroparesis Registry to Define Severity, Treatment Response, and Prognosis Using a Predominant-Symptom Classification Terminated NCT01173484

Search NIH Clinical Center for Idiopathic Gastroparesis

Genetic Tests for Idiopathic Gastroparesis

Anatomical Context for Idiopathic Gastroparesis

Publications for Idiopathic Gastroparesis

Articles related to Idiopathic Gastroparesis:

(show top 50) (show all 154)
# Title Authors PMID Year
1
Body weight in patients with idiopathic gastroparesis. 61
32930463 2021
2
Factors that contribute to the impairment of quality of life in gastroparesis. 61
33493377 2021
3
Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. 61
32693185 2021
4
Plasma endocannabinoids and cannabimimetic fatty acid derivatives are altered in gastroparesis: A sex- and subtype-dependent observation. 61
32779297 2021
5
Assessment of pyloric sphincter distensibility and pressure in patients with diabetic gastroparesis. 61
33314491 2020
6
Surgical Treatment for Refractory Gastroparesis: Stimulator, Pyloric Surgery, or Both? 61
31512100 2020
7
Clinical efficacy of gastric per-oral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: a systematic review and meta-analysis using surgical pyloroplasty as a comparator group. 61
31583465 2020
8
Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. 61
32493829 2020
9
Gastric peroral endoscopic pyloromyotomy versus gastric electrical stimulation in the treatment of refractory gastroparesis: a propensity score-matched analysis of long term outcomes. 61
32084672 2020
10
Open-label pilot study: Non-invasive vagal nerve stimulation improves symptoms and gastric emptying in patients with idiopathic gastroparesis. 61
31802596 2020
11
An emerging method to noninvasively measure and identify vagal response markers to enable bioelectronic control of gastroparesis symptoms with gastric electrical stimulation. 61
32087238 2020
12
Symptom variability throughout the day in patients with gastroparesis. 61
31782211 2020
13
The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review. 61
32256403 2020
14
Safety and Feasibility of Per-Oral Pyloromyotomy as Augmentative Therapy after Prior Gastric Electrical Stimulation for Gastroparesis. 61
31610231 2019
15
Proteomics in gastroparesis: unique and overlapping protein signatures in diabetic and idiopathic gastroparesis. 61
31482734 2019
16
Functional Emesis. 61
31517329 2019
17
Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study. 61
31295161 2019
18
Abdominal Pain in Patients with Gastroparesis: Associations with Gastroparesis Symptoms, Etiology of Gastroparesis, Gastric Emptying, Somatization, and Quality of Life. 61
30852767 2019
19
Transcriptome profiling reveals significant changes in the gastric muscularis externa with obesity that partially overlap those that occur with idiopathic gastroparesis. 61
31221130 2019
20
Opioid Use and Potency Are Associated With Clinical Features, Quality of Life, and Use of Resources in Patients With Gastroparesis. 61
30326297 2019
21
Case Report of gastroparesis healing: 16 years of a chronic syndrome resolved after proximal intercessory prayer. 61
30935546 2019
22
Pathophysiology of idiopathic gastroparesis and implications for therapy. 61
30638082 2019
23
Epidemiology and Pathophysiology of Gastroparesis. 61
30396519 2019
24
Diabetic Gastroparesis and Nondiabetic Gastroparesis. 61
30396524 2019
25
Bayesian inverse methods for spatiotemporal characterization of gastric electrical activity from cutaneous multi-electrode recordings. 61
31609972 2019
26
Sepiapterin alleviates impaired gastric nNOS function in spontaneous diabetic female rodents through NRF2 mRNA turnover and miRNA biogenesis pathway. 61
30285465 2018
27
Wisconsin's Enterra Therapy Experience: A multi-institutional review of gastric electrical stimulation for medically refractory gastroparesis. 61
30072246 2018
28
Pyloric sphincter characteristics using EndoFLIP® in gastroparesis. 61
29709494 2018
29
Efficacy of needleless transcutaneous electroacupuncture in synchronization with breathing for symptomatic idiopathic gastroparesis: A blinded and controlled acute treatment trial. 61
29745434 2018
30
Rome IV Diagnostic Questionnaire Complements Patient Assessment of Gastrointestinal Symptoms for Patients with Gastroparesis Symptoms. 61
29808246 2018
31
Transcriptomic signatures reveal immune dysregulation in human diabetic and idiopathic gastroparesis. 61
30086735 2018
32
Idiopathic gastroparesis is associated with specific transcriptional changes in the gastric muscularis externa. 61
29052298 2018
33
Therapeutic response to domperidone in gastroparesis: A prospective study using the GCSI-daily diary. 61
29110425 2018
34
Per oral endoscopic pyloromyotomy for refractory gastroparesis: initial results from a single institution. 61
28567693 2017
35
Gastroparesis: Medical and Therapeutic Advances. 61
28721575 2017
36
Gastric neuromuscular histology in patients with refractory gastroparesis: Relationships to etiology, gastric emptying, and response to gastric electric stimulation. 61
28374487 2017
37
Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum. 61
28066953 2017
38
Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. 61
27781342 2017
39
Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. 61
29161307 2017
40
Evaluation of prokinetic agents used in the treatment of gastroparesis. 61
28265483 2017
41
Gastroparesis as the Sole Presenting Feature of Neuromyelitis Optica. 61
29026864 2017
42
Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. 61
27350152 2016
43
Gastric Electrical Stimulation for Gastroparesis and Chronic Unexplained Nausea and Vomiting. 61
27678506 2016
44
Measures of Autonomic Dysfunction in Diabetic and Idiopathic Gastroparesis. 61
27785328 2016
45
Innovative gastric endoscopic muscle biopsy to identify all cell types, including myenteric neurons and interstitial cells of Cajal in patients with idiopathic gastroparesis: a feasibility study (with video). 61
27129395 2016
46
Pancreatic Adenocarcinoma Invading the Duodenum and Presenting as Idiopathic Gastroparesis with Nausea and Vomiting. 61
27807571 2016
47
Gastric Enterovirus Infection: A Possible Causative Etiology of Gastroparesis. 61
27344315 2016
48
Gastric peroral endoscopic pyloromyotomy (G-POEM) as a salvage therapy for refractory gastroparesis: a case series of different subtypes. 61
27197717 2016
49
[Gastroparesis - causes, diagnosis and treatment]. 61
27221182 2016
50
Hydration Strategy for Endurance Running in an Athlete Requiring Home Parenteral Nutrition. 61
26150104 2016

Variations for Idiopathic Gastroparesis

Expression for Idiopathic Gastroparesis

Search GEO for disease gene expression data for Idiopathic Gastroparesis.

Pathways for Idiopathic Gastroparesis

Pathways related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.47 GIP GHSR GHRL
2 11.11 PDGFRA HMOX1
3 9.92 GHSR GHRL

GO Terms for Idiopathic Gastroparesis

Cellular components related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynapse GO:0098794 9.26 GHSR GHRL
2 secretory granule lumen GO:0034774 9.16 GIP GHRL
3 cell surface GO:0009986 9.13 PDGFRA MRC1 GHSR
4 Schaffer collateral - CA1 synapse GO:0098685 8.62 GHSR GHRL

Biological processes related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 9.63 GHSR GHRL
2 female pregnancy GO:0007565 9.63 GIP GHSR
3 response to nutrient levels GO:0031667 9.62 GIP GHRL
4 negative regulation of tumor necrosis factor production GO:0032720 9.62 GHSR GHRL
5 negative regulation of interleukin-6 production GO:0032715 9.61 GHSR GHRL
6 response to estrogen GO:0043627 9.61 HMOX1 GHRL
7 response to hormone GO:0009725 9.6 GHSR GHRL
8 hormone-mediated signaling pathway GO:0009755 9.59 GHSR GHRL
9 negative regulation of interleukin-1 beta production GO:0032691 9.58 GHSR GHRL
10 positive regulation of insulin secretion GO:0032024 9.58 GIP GHRL
11 positive regulation of multicellular organism growth GO:0040018 9.57 GHSR GHRL
12 positive regulation of sprouting angiogenesis GO:1903672 9.56 GHSR GHRL
13 negative regulation of insulin secretion GO:0046676 9.55 GHSR GHRL
14 decidualization GO:0046697 9.54 GHSR GHRL
15 positive regulation of vascular endothelial cell proliferation GO:1905564 9.52 GHSR GHRL
16 actin polymerization or depolymerization GO:0008154 9.51 GHSR GHRL
17 regulation of postsynapse organization GO:0099175 9.49 GHSR GHRL
18 positive regulation of growth GO:0045927 9.48 GHSR GHRL
19 adult feeding behavior GO:0008343 9.46 GHSR GHRL
20 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.43 GHSR GHRL
21 growth hormone secretion GO:0030252 9.4 GHSR GHRL
22 positive regulation of eating behavior GO:1904000 9.37 GHSR GHRL
23 regulation of transmission of nerve impulse GO:0051969 9.32 GHSR GHRL
24 positive regulation of appetite GO:0032100 9.26 GHSR GHRL
25 regulation of gastric motility GO:1905333 9.16 GHSR GHRL
26 positive regulation of small intestine smooth muscle contraction GO:1904349 8.96 GHSR GHRL
27 positive regulation of small intestinal transit GO:0120058 8.62 GHSR GHRL

Molecular functions related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.62 GIP GHRL

Sources for Idiopathic Gastroparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....